Clinical trials: sponsored by Sanofi
Diabetes Mellitus
Effect of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin
Primary Objective: To evaluate the effects of rifampicin on the pharmacokinetics (PK) of sotagliflozin and its metabolite in healthy male and female subjects.
- Trial name
- NCT03063580
- Testing
- Sotagliflozin (SAR439954), Rifampicin
- Where
- France
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Sotagliflozin Bioequivalence Study
Primary Objective: To determine the bioequivalence of a single dose of the commercial tablet of sotagliflozin (test) compared to the development tablet of sotagliflozin (reference) under fasting conditions in healthy male and…
- Trial name
- NCT03211195
- Testing
- Sotagliflozin (SAR439954)
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Sanofi
Type 1 Diabetes
A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus
Primary Objective: To compare exposure and activity of SAR341402 to NovoRapid® and NovoLog®. Secondary Objective: To assess the safety and tolerability of SAR341402.
- Trial name
- NCT03202875
- Testing
- SAR341402, Insulin Aspart
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Sanofi
Rhinitis Allergic
A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR)
Primary Objective: To assess efficacy of Nasacort® (triamcinolone) nasal spray, 55 µg per dose, in comparison with Flixonase® (fluticasone) nasal spray, 50 µg per dose, by reflective total nasal symptom score (rTNSS) (24 h) after…
- Trial name
- NASANIF (NCT03317015)
- Testing
- triamcinolone XRG5029, fluticasone
- Volunteers
- 260 people
- Sponsor
- Sanofi
Epilepsy
Study of Excretion Balance and Pharmacokinetics of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female Subjects
Primary Objectives: To determine the excretion balance and systemic exposure of radioactivity after oral administration of [14C]-sodium valproate (VPA) .
- Trial name
- NCT03681158
- Testing
- sodium valproate
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Sanofi
Zika Virus Disease
Zika Case Definition and Surveillance Study
This prospective, surveillance study will assess the operational Zika virus definition for use in future Zika purified inactivated virus (ZIKV) vaccine efficacy trials in order to identify Zika virus disease (ZVD) cases among the…
- Trial name
- NCT03158233
- Where
- 6 sites in Colombia, Honduras and 2 more
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine
The aim of the study is to to assess the immunogenicity and safety of a quadrivalent influenza vaccine in a multi-dose presentation compared to a quadrivalent influenza vaccine in single-dose presentation, in children aged 6…
- Trial name
- NCT03391193
- Testing
- Multi-dose Quadrivalent Influenza Vaccine, Single-dose Quadrivalent Influenza Vaccine
- Where
- 3 sites in Mexico
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea
Primary Objective: To demonstrate the superiority of sotagliflozin dose 1 versus placebo on hemoglobin A1c (HbA1c) reduction in Chinese patients with type 2 diabetes (T2D) who have inadequate glycemic control on metformin alone…
- Trial name
- NCT03761134
- Testing
- sotagliflozin (SAR439954), metformin, sulfonylurea
- Where
- 40 sites in China
- Volunteers
- 377 people
- Sponsor
- Sanofi
Whooping Cough, Pertussis
Observational Study Describing the Immune Profile Induced By Pertussis Vaccines
This is an observational study designed to describe the immune profile of toddlers and preschoolers with acellular priming after receiving a booster dose of pertussis vaccine.
- Trial name
- NCT03147898
- Where
- 2 sites in Mexico, Panama
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
Primary Objective: To identify a best fasting plasma glucose (FPG) target for Chinese type 2 diabetes patients using insulin glargine which can provide the highest control rate of glycated hemoglobin (HbA1c) < 7%.
- Trial name
- NCT02545842
- Testing
- INSULIN GLARGINE
- Where
- 44 sites in China
- Volunteers
- 947 people
- Sponsor
- Sanofi
Gaucher Disease, Splenomegaly
A National Study in Patients With Unexplained Splenomegaly
Primary Objective: To estimate the prevalence of Gaucher disease and of other etiologies, in patients of 15 years old or more presenting with unexplained splenomegaly after exclusion of first intention-diagnoses (e.g.
- Trial name
- SMS (NCT04430881)
- Where
- France
- Volunteers
- 506 people
- Sponsor
- Sanofi
Type 1 Diabetes
Association of Type 1 Diabetes Mellitus in Offsprings With Positive Parental History of Diabetes
Primary Objective: To measure the association between a parental history of diabetes and the odds of an offspring being Type 1 diabetics. Secondary Objectives: To document the profile of Type 1 diabetes patients.
- Trial name
- SHINE (NCT03312478)
- Testing
- Blood draw for insulin auto-anti body tests*
- Where
- Pakistan
- Volunteers
- 375 people, healthy volunteers welcome
- Sponsor
- Sanofi
Microvascular Coronary Artery Disease
Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus
Primary Objective: To assess the pharmacodynamic effects of SAR247799 on macrovascular endothelial function of the brachial artery using flow-mediated dilation (FMD) in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03462017
- Testing
- SAR247799, Sildenafil, Acetylcholine
- Where
- 2 sites in Germany
- Volunteers
- 54 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy
Primary Objective: To test the hypothesis that basal insulin based treatment (G+) is noninferior to twice-daily premixed insulin (PM-2) in term of hemoglobin A1c (glycosylated hemoglobin, HbA1c) reduction from baseline to end of…
- Trial name
- SWITCH (NCT03359837)
- Testing
- INSULIN GLARGINE (HOE901), Insulin Glulisine, Biphasic insulin aspart 30
- Where
- China
- Volunteers
- 384 people
- Sponsor
- Sanofi
Tetanus, Diphtheria
DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants
Primary objective: To demonstrate the non-inferiority in terms of seroprotection rates (Hib antigen (PRP), Diphtheria, Tetanus, and Pertussis antigens (PT and FHA), and polio types 1, 2 and 3 antigens) of investigational arm…
- Conditions
- Tetanus, Diphtheria, Pertussis, Poliomyelitis
- Trial name
- NCT02274285
- Testing
- DTaP-IPV/Hib Combined vaccine, DTaP-IPV vaccine and Hib vaccine
- Where
- 12 sites in Japan
- Volunteers
- 424 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies
Immunogenicity and Safety of Verorab® in a "One-week" Intradermal Post-exposure Prophylaxis Regimen
The purpose of this study is to assess the 4-site "one-week" post-exposure prophylaxis (PEP) regimen as a possible alternative to the 2-site updated Thai Red Cross (TRC) PEP regimen.
- Trial name
- NCT01622062
- Testing
- PVRV, PVRV and pERIG Favirab®
- Where
- Philippines
- Volunteers
- 600 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Type 2 Diabetes Mellitus
A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects
Primary Objective: To assess in overweight to obese subjects the change in sleep energy expenditure after repeated subcutaneous (SC) doses of SAR425899.
- Trial name
- NCT03376802
- Testing
- SAR425899
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment
Primary Objective: The primary objective is to describe the effect of insulin glargine (U300) in type 2 diabetes mellitus (T2DM) patients uncontrolled with their current basal insulin therapy and eligible for basal switching…
- Trial name
- Transition II (NCT02967237)
- Testing
- insulin glargine (U300)
- Where
- 85 sites in France
- Volunteers
- 136 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)
Primary Objective: To demonstrate safety of 14-day repeated lixisenatide doses with 3 ascending doses as compared to placebo in pediatric patients with T2DM.
- Trial name
- NCT02803918
- Testing
- Lixisenatide (AVE0010), Basal Insulin, Metformin
- Where
- 11 sites in United States, Mauritius and 4 more
- Volunteers
- 23 people
- Sponsor
- Sanofi
Multiple Sclerosis Healthy Subjects
Single Ascending Dose Study of SAR443820 in Healthy Adult Chinese and Japanese Female and Male Participants
Primary Objective: To assess the pharmacokinetic parameters of SAR443820 after ascending single oral doses in healthy East Asian (Chinese and Japanese) adult participants.
- Trial name
- NCT04982991
- Testing
- RIPK1 inhibitor
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.